Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 808

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 808
---
 on the development milestones the Company has achieved prior to the termination of the Valent Assignment Agreement.

On September 30, 2014, the Company entered into an exchange agreement (the “Valent Exchange Agreement”) with Valent and Del Mar (BC). Pursuant to the Valent Exchange Agreement, Valent exchanged its loan payable in the outstanding amount of $ 279(including aggregate accrued interest to September 30, 2014, of $ 29), issued to Valent by Del Mar (BC), for 279shares of the Company’s Series A Preferred Stock. The Series A Preferred Stock has a stated value of $ 1.00per share (the “Series A Stated Value”) and is not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Series A Stated Value per year, payable quarterly in arrears. For the three and six months ended December 31, 2023, the Company recorded $ 2(2022 - $ 2 ) and $ 4 (2022 - $ 4 ), respectively, related to the dividends paid to Valent. The dividends have been recorded as a direct increase in accumulated deficit.

Related party payables

As of December 31, 2023, there is an aggregate amount of $ 148(June 30, 2023 - $ 298) payable to the Company’s officers and directors for fees, expenses, and accrued bonuses and other liabilities.

F-56

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted)

| 7 | Stockholders’ equity |

Preferred stock

Series C Preferred Stock

|                                                        |     | Series C Preferred Stock |        |   |     |                 |        |   |
|                                                        |     | Numberof shares          |        |   |     | $(in thousands) |        |   |
| Balance - June 30, 2023                                |     |                          | 14,208 |   |     |                 | 10,366 |   |
| Conversion of Series C Preferred stock to common stock |     |                          |   (540 | ) |     |                 |   (393 | ) |
| Balance - December 31, 2023                            |     |                          | 13,668 |   |